Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma.
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
15 09 2023
15 09 2023
Historique:
received:
23
12
2022
revised:
05
04
2023
accepted:
21
06
2023
medline:
18
9
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
ppublish
Résumé
Circular RNAs (circRNA) contribute to cancer stemness, proliferation, and metastasis. The biogenesis of circRNAs can be impacted by the genetic landscape of tumors. Herein, we identified a novel circRNA, circARFGEF2 (hsa_circ_0060665), which was upregulated in KRASG12D pancreatic ductal adenocarcinoma (PDAC) and positively associated with KRASG12D PDAC lymph node (LN) metastasis. CircARFGEF2 overexpression significantly facilitated KRASG12D PDAC LN metastasis in vitro and in vivo. Mechanistically, circARFGEF2 biogenesis in KRASG12D PDAC was significantly activated by the alternative splicing factor QKI-5, which recruited U2AF35 to facilitate spliceosome assembly. QKI-5 bound the QKI binding motifs and neighboring reverse complement sequence in intron 3 and 6 of ARFGEF2 pre-mRNA to facilitate circARFGEF2 biogenesis. CircARFGEF2 sponged miR-1205 and promoted the activation of JAK2, which phosphorylated STAT3 to trigger KRASG12D PDAC lymphangiogenesis and LN metastasis. Importantly, circARFGEF2 silencing significantly inhibited LN metastasis in the KrasG12D/+Trp53R172H/+Pdx-1-Cre (KPC) mouse PDAC model. These findings provide insight into the mechanism and metastasis-promoting function of mutant KRAS-mediated circRNA biogenesis. Increased splicing-mediated biogenesis of circARFGEF2 in KRAS-mutant pancreatic ductal adenocarcinoma activates JAK2-STAT3 signaling and triggers lymph node metastasis, suggesting circARFGEF2 could be a therapeutic target to inhibit pancreatic cancer progression.
Identifiants
pubmed: 37363990
pii: 727513
doi: 10.1158/0008-5472.CAN-22-3997
pmc: PMC10502454
doi:
Substances chimiques
MicroRNAs
0
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
RNA, Circular
0
KRAS protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3077-3094Informations de copyright
©2023 The Authors; Published by the American Association for Cancer Research.
Références
J Clin Invest. 2014 Mar;124(3):922-8
pubmed: 24590277
Cell. 2022 Jun 9;185(12):2016-2034
pubmed: 35584701
Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19061-6
pubmed: 20956316
Clin Cancer Res. 2010 Jun 1;16(11):2921-6
pubmed: 20460490
J Hematol Oncol. 2022 May 23;15(1):70
pubmed: 35606824
Trends Cell Biol. 2020 Mar;30(3):226-240
pubmed: 31973951
Cell. 2015 Mar 12;160(6):1125-34
pubmed: 25768908
Theranostics. 2022 May 16;12(9):4269-4287
pubmed: 35673576
Trends Immunol. 2022 Aug;43(8):674-686
pubmed: 35850914
Circ Res. 2018 Jan 19;122(2):246-254
pubmed: 29133306
Signal Transduct Target Ther. 2021 Nov 15;6(1):386
pubmed: 34776511
Wiley Interdiscip Rev RNA. 2022 Nov;13(6):e1724
pubmed: 35298877
Sci Transl Med. 2021 Oct 13;13(615):eabf7860
pubmed: 34644147
JAMA. 2021 Sep 7;326(9):851-862
pubmed: 34547082
Nucleic Acids Res. 2017 Apr 20;45(7):4021-4035
pubmed: 27928058
Trends Cancer. 2020 Apr;6(4):319-336
pubmed: 32209446
Nat Methods. 2022 Oct;19(10):1208-1220
pubmed: 35618955
Nat Rev Cancer. 2022 Mar;22(3):131-142
pubmed: 34789870
J Clin Invest. 2023 Mar 15;133(6):
pubmed: 36719747
J Clin Invest. 2022 Jul 15;132(14):
pubmed: 35838046
EMBO Rep. 2020 Apr 3;21(4):e48467
pubmed: 32052578
Nat Rev Clin Oncol. 2020 Aug;17(8):457-474
pubmed: 32303702
Nucleic Acids Res. 2019 Nov 18;47(20):10564-10579
pubmed: 31602485
Nat Commun. 2021 Jan 4;12(1):89
pubmed: 33397958
Gut. 2023 Feb;72(2):360-371
pubmed: 35623884
Cancer Discov. 2022 Apr 1;12(4):924-937
pubmed: 35046095
Annu Rev Cell Dev Biol. 2022 Oct 6;38:263-289
pubmed: 35609906
Nat Rev Gastroenterol Hepatol. 2020 Mar;17(3):153-168
pubmed: 32005945
Cancer Res. 2010 Nov 1;70(21):8842-51
pubmed: 20978206
Trends Mol Med. 2022 Jun;28(6):530
pubmed: 35504806
Cancer Cell. 2018 Sep 10;34(3):439-452.e6
pubmed: 30205046
Genome Biol. 2021 Oct 14;22(1):290
pubmed: 34649616
Nucleic Acids Res. 2016 Apr 7;44(6):2475-90
pubmed: 26926106
Adv Sci (Weinh). 2022 Jun;9(17):e2104986
pubmed: 35403823
Clin Cancer Res. 2010 Dec 1;16(23):5722-33
pubmed: 20921210
Gut. 2019 Oct;68(10):1893-1899
pubmed: 31227590
Nature. 2005 May 12;435(7039):224-8
pubmed: 15889096
J Clin Oncol. 2022 Aug 20;40(24):2693-2705
pubmed: 35839440
Nat Commun. 2021 Apr 1;12(1):2038
pubmed: 33795683
Nat Rev Drug Discov. 2020 Aug;19(8):533-552
pubmed: 32528145
Mol Cell. 2018 Aug 2;71(3):428-442
pubmed: 30057200
Nat Rev Mol Cell Biol. 2020 Aug;21(8):475-490
pubmed: 32366901
Clin Cancer Res. 2008 Sep 15;14(18):5759-68
pubmed: 18794085
Sci Rep. 2016 Nov 28;6:37982
pubmed: 27892494
Genome Biol. 2004;5(12):253
pubmed: 15575979
Nat Commun. 2021 Mar 9;12(1):1537
pubmed: 33750804
Eur Heart J. 2022 Nov 7;43(42):4496-4511
pubmed: 35758064
Theranostics. 2019 May 26;9(12):3526-3540
pubmed: 31281495